Compounds in this category
DSIP (delta sleep-inducing peptide) is the namesake of the category. It is a nonapeptide first isolated from rabbit cerebral venous blood by Schoenenberger and Monnier in 1977. The original animal studies reported induction of delta-wave EEG activity after intracerebroventricular administration. Subsequent peripheral administration studies in rodents and humans produced mixed results. A handful of small human trials in chronic insomnia patients reported reduced sleep latency and increased total sleep time. Sample sizes were small (under 30 subjects). The replication base outside the original research group is thin.
The honest evidence picture on DSIP is that the receptor target remains uncharacterized. The compound's effect on sleep in humans, as observed in published trials, is real but small and inconsistent. It is sold as a research chemical under Research Use Only (RUO) labeling. Not FDA-approved. Not EMA-approved.
Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson's group in St. Petersburg starting in the 1990s. The proposed mechanism involves pineal gland modulation and indirect support of nocturnal melatonin secretion. Rodent studies report improvements in age-related circadian disruption. Human evidence is limited to small open-label studies, mostly Russian-language, reporting subjective sleep improvement in elderly subjects. Independent Western replication is absent. The compound is sold as a research chemical.
MK-677 (ibutamoren) is an orally active non-peptide growth hormone secretagogue. It is the only compound in this category with substantial placebo-controlled human trial data, though not specifically for insomnia as the primary endpoint. Trials in healthy older adults and in obesity populations reported raised GH and IGF-1 with associated improvements in slow-wave sleep duration on polysomnography. The drug was investigated for sarcopenia and frailty and never reached FDA approval. It is WADA-prohibited and is sold as a research chemical for non-medical use.
Pinealon is another Khavinson tripeptide, marketed as a pineal-axis modulator. Animal data is published in small volume. Western clinical replication is almost entirely absent. The compound page reports what the source literature reports, not what marketing claims.
Mechanism overlap and divergence
Sleep peptides in this category act through unrelated mechanisms. DSIP is proposed to modulate hypothalamic sleep-regulatory networks through an undefined receptor. Epitalon and Pinealon are positioned as pineal-axis modulators, with effects on melatonin and circadian gene expression. MK-677 raises endogenous growth hormone, which has known effects on slow-wave sleep architecture observed since the 1960s. Three different mechanisms. Three different evidence tiers. They are not interchangeable.
The cleanest evidence in this category is for the GH-sleep axis effect of MK-677 in older adults with declining GH secretion. The shakiest evidence is the DSIP literature, where decades of small studies have not produced a definitive trial. Khavinson peptides occupy the middle, with mechanistic plausibility and thin clinical confirmation.
What this category does not include
Conventional sleep pharmaceuticals (benzodiazepines, Z-drugs, dual orexin receptor antagonists, melatonin agonists like ramelteon) are not peptides and do not appear in this category. Readers comparing peptide options to approved insomnia drugs should weigh the trial-stage difference carefully. A 12-subject open-label study reporting subjective sleep improvement is not equivalent to a placebo-controlled Phase 3 trial in chronic insomnia patients.
Regulatory note. None of the peptides in this category are approved for the treatment of insomnia. MK-677 reached late-stage development and was discontinued. DSIP and the Khavinson peptides remain investigational or are sold as research chemicals. Where dosing is reported on each compound page, it is from the cited literature, not framed as personal advice. Persistent insomnia warrants medical evaluation, not self-experimentation with unapproved compounds.